8-K current report · filed Nov 10, 2026

Lantheus Holdings, Inc. (LNTH) 8-K Current Report: November 10, 2026

Item 8.01LNTH overview

Short answer

Lantheus Holdings, Inc. (LNTH) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 8.01 (Other Events). Definitive agreement to sell CDMO business and Springfield, New Jersey facility to PharmaLogic.

Lantheus Holdings, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • Definitive agreement to sell CDMO business and Springfield, New Jersey facility to PharmaLogic
  • Sale remains subject to customary closing conditions and potential regulatory approvals
  • Transition services required immediately after closing, creating near-term execution obligations
  • Long-term supply agreement shifts lutetium Lu 177 dotatate manufacturing to PharmaLogic’s Agilera franchise
  • Transaction separates Lantheus from CDMO operations while preserving supply access for a key product

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Lantheus Holdings, Inc. 8-K filings

Get the next LNTH 8-K as it lands

Follow LNTH for push alerts, or ask the research agent what this filing means.